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Refractory acute graft-versus-host disease (aGVHD) is a major cause of death after allogeneic hematopoietic
stem cell transplantation. This study evaluated the immunomodulation effects of mesenchymal stromal cells
(MSCs) from bone marrow of a third-party donor for refractory aGVHD. Forty-seven patients with refractory
aGVHD were enrolled: 28 patients receiving MSC and 19 patients without MSC treatment. MSCs were given at
a median dose of 1  106 cells/kg weekly until patients got complete response or received 8 doses of MSCs.
After 125 doses of MSCs were administered, with a median of 4 doses (range, 2 to 8) per patient, overall
response rate was 75% in the MSC group compared with 42.1% in the non-MSC group (P ¼ .023). The incidence
of cytomegalovirus, Epstein-Barr virus infections, and tumor relapse was not different between the 2 groups
during aGVHD treatment and follow-up. The incidence and severity of chronic GVHD in the MSC group were
lower than those in the non-MSC group (P ¼ .045 and P ¼ .005). The ratio of CD3þCD4þ/CD3þCD8þ T cells, the
frequencies of CD4þCD25þFoxp3þ regulatory T cells (Tregs), and the levels of signal joint T cellereceptor
excision DNA circles (sjTRECs) after MSCs treatment were higher than those pretreatment. MSC-treated
patients exhibited higher Tregs frequencies and sjTRECs levels than those in the non-MSC group at 8 and
12 weeks after treatment. MSCs derived from bone marrow of a third-party donor are effective to refractory
aGVHD. It might reduce the incidence and severity of chronic GVHD in aGVHD patients by improving thymic
function and induction of Tregs but not increase the risks of infections and tumor relapse.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an effective therapy for several hematological
disorders. Although good progress has been made in the
prevention and treatment of side effects associated with
transplantation, acute graft-versus-host disease (aGVHD)
remains a common and life-threatening complication with
poor prognosis. Depending on the extent of HLA-identicaldgments on page 103.
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ty for Blood and Marrow Transplantation.sibling and donor source, aGVHD occurs in 30% to 80% of
recipients [1-3]. Corticosteroids are still considered as ﬁrst-
line treatment of aGVHD, with a response rate of 50% to
80% [3,4]. However, those who failed initial therapy only
showed a 10% to 30% chance of long-term survival [1,5,6].
Mesenchymal stromal cells (MSCs) are a form of multi-
potent adult stem cells that can be isolated from many tis-
sues, such as bone marrow (BM), adipose tissue, and
umbilical cord [7,8]. Such cells possess the capacity to sup-
press immunological responses, support hematopoiesis, and
repair tissues [9-11]. Clinical applications of humanMSCs are
evolving rapidly for preventing and treating GVHD [10,12-
14]. Although results are still controversial, most prospec-
tive and retrospective data suggest that MSCs are effective
for aGVHD [10,12,15-18]. MSCs modulate GVHD by
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the generation of regulatory T cells (Tregs), and these
immunosuppressive effects might increase the risks of
infection and tumor relapse. These studies, however, are
mostly from in vitro and preclinical studies, and few reports
have shed light on the effects of MSCs on the patient’s im-
mune system. The incidence and severity of chronic GVHD
(cGVHD) are rarely reported in refractory aGVHD patients
treated with MSCs.
In this prospective study, we evaluate the efﬁcacy of
ex vivoeexpanded MSCs from BM of a third-party donor to
refractory aGVHD. In addition, we discuss some challenges
that remain to be addressed in clinical applications of MSCs.
METHODS
Study Design and Patient Eligibility
In this prospective, open-label, nonrandomized, multicenter study, each
patient was prospectively and consecutively enrolled. Diagnosis of aGVHD
was according to the literature criteria deﬁned by the Consensus Workshop
[19]. Refractory aGVHDwas deﬁned as resistance to ﬁrst-line treatment with
corticosteroids and at least one second-line therapy. Steroid-resistant
aGVHD was deﬁned as progression of disease in the ﬁrst 72 hours of ste-
roid treatment with methylprednisone (2 mg/kg/day) or lack of response
after 7 days of treatment with methylprednisone [20]. One second-line
therapy failure was deﬁned as progressive or persistent aGVHD symptoms
despite 5 days of second-line therapy protocols, such as mycophenolate
mofetil, cyclophosphamide, methotrexate, CD25 monoclonal antibody, and
human antithymocyte globulin [5]. When possible, we conﬁrmed the
diagnosis of GVHD with biopsy of the involved organs.
Patients were eligible if they developed refractory aGVHD. Patients were
excluded if they had irreversible organ failure and/or any abnormality in
vital signs (e.g., heart rate, respiratory rate, or blood pressure). This study
was performed in accordance with the tenets of the modiﬁed Helsinki
Declaration, and our protocol was approved by the respective ethics review
boards before initiation of the study. All recipients and/or guardians and
donors gave written informed consent to participate in the study.
MSC Manufacture
MSCs were manufactured and provided by the Center for Stem Cell
Biology and Tissue Engineering, Sun Yat-Sen University. BM-derived MSCs
were obtained from HLA-mismatched third-party donors after written
informed consent. Isolation and ex vivo expansion of MSCs were performed
according to methods described previously [21]. Brieﬂy, MSCs were isolated
from BM and cultured in human MSC growth medium consisting of low
glucose DMEM (Hyclone, Logan, UT) and 10% FBS (Hyclone) at a density of
5  103 cells/cm2. After 3 days, nonadherent cells were removed and me-
dium replaced. Adherent cells were further cultured, with a change of me-
dium every 3 days. When monolayers attained 70% to 80% conﬂuence, cells
were detached and passaged. Cells were harvested after 4 to 5 passages and
administered to patients. The antigen expressions of MSCs were detected
with ﬂow cytometry. The culture-expanded cells expressed CD29, CD44,
CD73, CD90, CD105, and CD166 but not CD11a, CD34, and CD45. The cells
could be induced to differentiate into cells of the osteogenic, adipogenic, and
chondrogenic lineages when cultured in appropriate induction medium and
could inhibit mixed lymphocyte cultures in vitro. The characteristics of
human MSCs are shown in Figure 1.
Therapeutic Schedule
In the MSC group, MSCs were administered in combination with pre-
existing aGVHD treatments in accordance with individual institutional
guidelines. MSCs were given at a median dose of 1  106 cells/kg once
weekly, until aGVHD showed a complete response (CR) or MSCs had been
administered for a total of 8 doses. If symptoms of aGVHD persisted or
progressed after 2 doses of MSC infusion, pre-existing aGVHD treatments
were possibly changed, which was decided by the attending physician. In
the non-MSC group, salvage treatments for refractory aGVHD were left to
the clinical judgment of the treating teams.
Monitoring of Cytomegalovirus-DNA and Epstein-Barr ViruseDNA
Loads in Blood
Generally, cytomegalovirus (CMV)-DNA and Epstein-Barr virus (EBV)-
DNA loads of blood were detected as our previous study [22]. In our study,
CMV-DNA and EBV-DNAwere monitored twice a week until a CR in aGVHD
was achieved or until the end of treatments. For the ﬁrst 6 months of the
1-year follow-up, themonitoring frequencywas once aweek. For the second6 months of the 1-year follow-up, the frequency was changed to once every
2 weeks.
Detection of Lymphocyte Subsets and Signal Joint T CelleReceptor
Excision DNA Circles in Peripheral Blood
Patients’ blood samples were collected before study treatments and at 4,
8, 12, 24, and 36 weeks after study treatments. T lymphocyte subsets (CD3þ,
CD3þCD4þ, CD3þCD8þ, CD4þCD25þFoxp3þ) and B lymphocytes (CD19þ) in
peripheral blood were analyzed by ﬂow cytometry. Quantiﬁcation of signal
joint T cellereceptor excision DNA circles (sjTRECs) were analyzed by real-
time PCR according to methods described previously [23]. A duplex vector
that included a fragment of the dRec-jJa sjTREC and a fragment of the RAG2
were used to precisely determine the percentage of cells carrying sjTREC.
The ampliﬁcationwas performed onMJ Research DNA Engine Opticon 2 PCR
cycler (Bio-Rad, Hercules, CA, USA).
Evaluation Points and Statistical Analyses
In this study, evaluation points were the immunomodulation effects of
MSCs, including the efﬁcacy of MSCs for refractory aGVHD, infections, tumor
relapse, and cGVHD after MSC treatment. The responses to aGVHD were
according to the literature criteria, including CR, partial response (PR), and
no response. CR was deﬁned as resolution of all symptoms of aGVHD, and PR
was deﬁned as a decrease by at least 1 GVHD stage in any 1 organ system
without deterioration in others [24]. Overall response (OR) included CR and
PR. Infections were mainly focused on CMV and EBV infections during study
treatments and within 1 year after study treatments. CMV and EBV in-
fections were divided into viremia and associated diseases. The diagnosis
criteria of those were deﬁned by published recommendations and the
criteria of the European Conference on Infections [25,26]. Tumor relapsewas
deﬁned according to previously published criteria [27,28]. Diagnosis of
cGVHD was based on published classiﬁcations [29]. De novo aGVHD was
deﬁned as aGVHD occurring after conventional GVHD prophylaxis, and
secondary aGVHD was deﬁned as aGVHD occurring after tapering/dis-
continuing immunodepressants or donor lymphocyte infusion. Adverse
events were assessed by the National Cancer Institute Common Toxicity
Criteria for Adverse Events (CTCAE version 3.0) [30].
The SPSS software package (SPSS, Chicago, IL) was used to process all
data. Patient-, disease-, and treatment-related variables for patients in the
MSC and non-MSC groups were compared using the chi-square test. Safety
evaluations in the compared groupswere explored using chi-square test and
Fisher exact tests for small numbers. Differences among lymphocyte subsets
before and after MSC treatment and differences between the 2 groups were
assessed using Student’s t-test. The Mann-Whitney U-test was used to
compare the difference in levels or frequencies of sjTRECs between the 2
groups. OS was calculated from the date of HSCT to death or to last follow-
up, and disease-free survival was calculated from the date of HSCT to death,
tumor relapse, or last follow-up. Incidence of time-dependent variables was
estimated by the method of Kaplan-Meier. EBV and CMV infections as well
as OS and disease-free survival were entered as time-dependent covariates.
Two-sided P < .05 was considered to be statistically signiﬁcant.
RESULTS
Patients, Transplantation, and aGVHD Characteristics
Forty-seven refractory aGVHD patients were conducted
from March 2010 to March 2013 at Nanfang Hospital,
SouthernMedical University; Guangzhou General Hospital of
Guangzhou Military Command; and SUN Yat-Sen Memorial
Hospital, SUN Yat-Sen University. Based on the voluntary
principle, 28 patients accepted MSC treatment, and 19
patients treated without MSCs acted as the control group.
Conditioning regimens and GVHD prophylaxis were per-
formed according to the strategy described previously [21].
The patients in the MSC group had similar characteristics to
those in the control group in age, gender, primary diseases,
diseases status before transplant, and transplantation char-
acteristics. In theMSC group, 22 patients had de novo aGVHD
and 6 had secondary aGVHD (4 cases occurred after donor
lymphocyte infusion and 2 after tapering immunode-
pressants). In the control group, 15 patients had de novo
aGVHD and 4 had secondary aGVHD (2 cases occurred after
donor lymphocyte infusion and 2 after tapering immuno-
depressants). Table 1 presents detailed information of the 2
groups.
Figure 1. Characteristics of human MSCs. (A) The morphology of human MSCs (passage 4) monitored by phase contrast microscopy. (B) Oil red O staining of adi-
pogenic differentiated human MSCs. (C) Alizarin red S staining of osteogenic differentiated human MSCs. (D) Flow cytometric analysis of surface markers of human
MSCs. Scale bar ¼ 200 mm.
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All patients received methylprednisolone combined with
calcineurin inhibitors as ﬁrst-line treatments for aGVHD. Of
the 28 patients treated with MSCs, 4 received 1 second-line
immunosuppressant and 24 received 2 or more immuno-
suppressants, includingmethotrexate (n¼8),mycophenolate
mofetil (n ¼ 10), antithymocyte globulin (n ¼ 12), cyclo-
phosphamide (n ¼ 13), and CD25 monoclonal antibody
(n¼ 17). Themedian time of immunosuppressant treatments
beforeMSCs was 17 days (range,11 to 55), including ﬁrst-line
therapy for 7 days (range, 5 to 14) and second-line therapy for
11 days (range, 6 to 41). In the control group, all patients
received 2 or more second-line immunosuppressant therapy
for refractory aGVHD, including methotrexate (n ¼ 7),
mycophenolate mofetil (n ¼ 9), cyclophosphamide (n ¼ 11),
CD25 monoclonal antibody (n ¼ 12), and antithymocyte
globulin (n ¼ 13). At the onset of MSC treatment, 4 patients
had grade II, 8 had grade III, and 16had grade IV aGVHD. In the
control group, 2 patients had grade II, 8 had grade III, and 9
had grade IV aGVHD. No statistical signiﬁcance was found
between the 2 groups for the onset grade of aGVHD and pre-
existing second-line immunosuppressants treatments.
Treatment and Outcome
In the MSC group, 125 doses of MSCs were administered
in 28 refractory aGVHD patients, with a median of 4 doses
(range, 2 to 8) per patient. Twenty-four of 28 patientsreceiving MSCs derived from 2 or more donors had an OR
rate of 75% (21/28), including CR in 17 patients (60.7%) and
PR in 4 (14.3%). After 4 doses of MSC infusions, 18 of 28
patients (64.3%) had an initial response, including CR in 10
(35.7%) and PR in 8 (28.6%). Over the period of aGVHD
treatments 7 patients died, and causes of death were aGVHD
progression (n ¼ 3), infections (n ¼ 2), diffuse alveolar
hemorrhage (n ¼ 1), and brainstem hemorrhage (n ¼ 1). In
the control group, the OR rate was 42.1% (8/19), including CR
in 5 patients (26.3%) and PR in 3 (15.8%). During the corre-
sponding period, 11 patients died, 7 from aGVHD progression
and 4 from infections. The OR and CR rates in the MSC group
were both signiﬁcantly higher than those in the control
group (P ¼ .023 and P ¼ .020, respectively).
To evaluate the factors inﬂuencing the efﬁcacy of MSCs to
aGVHD, the grade and type of aGVHD (de novo aGVHD and
secondary aGVHD), the organ affected by aGVHD, and the
number of involved organs were analyzed. Results showed
the CR rate of grade IV aGVHD (37.5%) was signiﬁcantly lower
than that of grades II (100%) and III (87.5%) aGVHD (P ¼ .014).
The CR rate of secondary aGVHD was 40% (3/6) and of de
novo aGVHD 60% (14/22) (P ¼ .544). The CR rate of aGVHD
with different aGVHD target organs was similar in skin
(73.9%), gut (69.2%), and liver (47.3%) (P ¼ .307). The CR rate
of aGVHD with single-organ involvement (100%) was
signiﬁcantly higher than those with two or more organs
involved (52.1%) (P ¼ .047).
Table 1
Characteristics of Patients, Transplants, and aGVHD in the MSC and Non-
MSC Group
MSC Group
(n ¼ 28)
Non-MSC Group
(n ¼ 19)
P
Female/male 9/19 7/12 .739
Median age, yr (range) 26 (14-54) 29 (14-50) .455
Primary diseases .827
AML 9 7
ALL 14 10
CML 4 2
NHL 1 0
Disease status at time of
transplantation
.847
CR (including CML-CP) 11 8
NR (including CML-AP and BP) 17 11
Donor type
Related donor/unrelated donor 19/9 12/7 .739
HLA typing .813
HLA-identical 17 8
One allele mismatched 5 5
Two alleles mismatched 2 2
Three alleles mismatched 3 3
Four alleles mismatched 0 0
Five alleles mismatched 1 1
Stem cell source
PBSCs/PBSCs þ BM 21/7 14/5 .698
aGVHD post-DLI
Yes/no 6/22 4/15 .737
Onset grade of aGVHD .491
II 4 2
III 8 8
IV 16 9
aGVHD involved organs .603
Gastrointestinal 24 13
Skin 21 16
Liver 16 9
Lung 3 1
Onset of aGVHD
Median days (range) 37 (14-121) 33 (17-116) .827
Conditioning .978
TBI þ CY 3 3
Bu þ CY 4 4
Bu þ Flu 4 2
Flu þ Ara-c þTBI þ CY 10 7
TBI þ CY þ VP-16 7 3
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin lym-
phoma; CP, chronic phase; NR, not in CR; AP, accelerated phase; BP, blastic
phase; PBSCs, peripheral blood stem cells; DLI, donor lymphocyte infusion;
TBI, total body irradiation; CY, cyclophosphamide; Bu, busulfan; Flu,
ﬂudarabine; Ara-c, cytarabine; VP-16, etoposide.
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To prevent invasive fungal diseases, all patients received
antifungal prophylaxis during aGVHD treatment. Table 2
shows detailed information of infections between the 2
groups. In the MSC-treated group, 11 patients were experi-
encing infections at the onset time of MSC treatment. Ten of
them were under control, and 1 patient with invasive fungal
disease progressed during the study treatments. During MSC
treatment, 14 patients developed 16 new episodes of in-
fections, and 2 patients died of infections (1 septic shock and
1 EBV-associated diseases). In the control group, 8 patients
were experiencing infections at the onset of study treat-
ments. Seven of them were under control, and 1 patient
(mixed infections) progressed during the study treatments.
During the period of study treatment, 13 patients developed
17 new episodes of infections, and 4 died of infections (2
septic shock, 1 CMV-associated diseases, and 1 EBV-
associated diseases). The incidence rate of infectious epi-
sodes between the 2 groups was not signiﬁcantly different
during the study treatments (P ¼ .210).The incidence of CMV and EBV viremia and CMV-and
EBV-associated diseases was 39.3% (11/28), 25% (7/28),
14.3% (4/28), and 14.3% (4/28), respectively, during MSC
treatment in the MSC group, compared with 36.8% (7/19),
31.5% (6/19), 5.26% (1/19), and 10.5% (2/19), respectively,
during aGVHD treatment in the control group (P ¼ .866 and
P ¼ .621, P ¼ .325 and P ¼ .705, respectively). The 1-year
cumulative incidence of CMV and EBV viremia and associ-
ated diseases is shown in Figure 2. The incidence of CMV and
EBV viremia and associated diseases was not different be-
tween the 2 groups during GVHD treatment and within 1
year after GVHD treatments.Chronic GVHD
Thirty-ﬁve patients who survived more than 60 days after
aGVHD were evaluated for the incidence and severity of
cGVHD: 23 cases in the MSC group and 12 cases in the con-
trol group. Five patients (21.7%) had cGVHD (4 limited and 1
extensive cGVHD) and no patient died from cGVHD in the
MSC group, whereas 7 patients (58.3%) had cGVHD (2 limited
and 5 extensive cGVHD) and 2 patients died from cGVHD in
the control group. The 2-year cumulative incidence of cGVHD
was 31.5% 10.1% in the MSC group and 79.2%  12.7% in the
control group (P ¼ .045). The extensive cGVHD (1/23) in the
MSC group was also signiﬁcantly lower than that (5/12) in
the control group (P ¼ .005).Lymphocyte Subset Analysis
The changes in lymphocyte subsets in peripheral blood
between the 2 groups are shown in Figure 3. In the MSC
group, the frequency of CD3þCD8þ T cells was signiﬁcantly
decreased at 8 weeks, compared with pre-MSC treatment
(26.743%  11.10% versus 46.882%  12.10%, P ¼ .013), and
was sustained to 24 weeks after MSC treatment (Figure 3B).
The frequency of CD3þCD4þ T cells was not signiﬁcantly
different during the monitoring time (Figure 3A). The ratio of
CD3þCD4þ/CD3þCD8þ T cells increased signiﬁcantly at 8
weeks (P ¼ .038) and was sustained to 36 weeks after MSC
treatment. Compared with pre-MSC treatment, the fre-
quency of CD4þCD25þFoxp3þ Tregs showed a signiﬁcant
increase at 8 weeks (1.212%  1.8% versus 4.130%  2.8%,
P¼ .012) and was sustained to 36 weeks after MSC treatment
(Figure 3C). The frequency of CD19þ B cells did not change
signiﬁcantly before and after MSC treatment.
In the control group, the frequencies of CD3þCD4þ and
CD3þCD8þ T cells all decreased at 4, 8, and 12 weeks and
then gradually increased at 24 and 36 weeks after treatment
but did not show a signiﬁcant difference compared with
pretreatment (Figure 3A,B). The ratio of CD3þCD4þ/
CD3þCD8þ and the frequency of CD4þCD25þFoxp3þ Tregs
did not signiﬁcantly change before and after treatment.
A signiﬁcant difference was not evident between patients
with MSC and non-MSC treatment in terms of the fre-
quencies of CD3þCD4þ and CD3þCD8þ T cells, CD19þ B cells,
and CD4þCD25þFoxp3þ Tregs before treatments. Comparing
the MSC group with the non-MSC group, the ratio of
CD3þCD4þ/CD3þCD8þ T cells was higher at 12 weeks after
study treatment in the MSC group (P ¼ .046), and the level in
the 2 groups gradually approached at 24 and 36 weeks
(P ¼ .660 and P ¼ .739, respectively). As shown in Figure 3C,
the frequencies of CD4þCD25þFoxp3þ Tregs were signiﬁ-
cantly higher in the MSC group at 8 and 12 weeks after
treatment (4.130%  2.8% versus 2.010%  2.1%, P ¼ .026;
3.890%  2.6% versus 2.372%  3.3%, P ¼ .029), compared
Table 2
Status and Outcomes of Infections between the MSC and Non-MSC Groups
MSC Group (n ¼ 28) Non-MSC Group (n ¼ 19)
Onset Time of Study
Treatment
During Study Treatment Onset Time of Study
Treatment
During Study Treatment
n Outcomes n Outcomes n Outcomes n Outcomes
Under
Control
Progression/
Death
Under
Control
Progression/
Death
Under
Control
Progression/
Death
Under
Control
Progression/
Death
Episodes of infections 11 10 1/0 16 14 2/2 8 7 1/0 17 13 4/4
Bacterial 7 7 0/0 6 5 1/1 5 5 0/0 7 5 2/2
Fungal 2 1 1/0 0 0 0/0 2 2 0/0 3 3 0/0
Virus 0 0 0/0 5 4 1/1 0 0 0/0 2 0 2/2
CMV-associated
diseases
0 0 0/0 3 3 0/0 0 0 0/0 1 0 1/1
EBV-associated
diseases
0 0 0/0 2 1 1/1 0 0 0/0 1 0 1/1
Mixed infections 2 2 0/0 5 5 0/0 1 0 1/0 5 5 0/0
Bacterial and fungal 2 2 0/0 2 2 0/0 1 0 1/0 4 4 0/0
Bacterial, fungal, and
viral
0 0 0/0 3 3 0/0 0 0 0/0 1 1 0/0
CMV and EBV viremia were not considered as infections.
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signiﬁcant differences were found between the 2 groups.
sjTREC
To investigate the roles of MSCs in the thymus, we eval-
uated thymic output function through sjTREC in 14 aGVHD
patients from October 2012 to March 2013, including 8
receiving MSC treatment and 6 non-MSC treatment. The
levels of sjTREC in healthy control subjects were as reportedFigure 2. Cumulative incidence of CMV viremia (A), CMV-associated diseases (B), EBV
of CMV viremia and CMV-associated diseases was 53.1%  6.5% and 18.5%  5.8% in th
(P ¼ .488 and P ¼ .215). The 1-year cumulative incidence of EBV viremia and EBV-assoc
with 37.4%  8.2% and 12.8%  4.3% in the control group (P ¼ .597 and P ¼ .478).previously [23]. Our results showed that sjTREC levels in
patients with refractory GVHD were signiﬁcantly lower than
those in healthy control subjects (near baseline .013  .035
copies/1000 peripheral blood mononuclear cells [PBMCs]
versus 3.011  .838 copies/1000 PBMCs, P ¼ .001), and no
evident differences were shown between patients in theMSC
and non-MSC groups before the study treatment (.014 .027
copies/1000 PBMCs versus .011  .021 copies/1000 PBMCs,
P ¼ .870). The levels of sjTREC signiﬁcantly increased atviremia (C), and EBV-associated diseases (D). The 1-year cumulative incidence
e MSC group compared with 46.9%  7.3% and 6.2%  5.1% in the control group
iated diseases was 30.8%  10.1% and 24.3%  6.7% in the MSC group compared
Figure 3. Lymphocyte subsets of CD3þCD4þ T cells (A), CD3þCD8þ T cells (B), and CD4þCD25þFoxp3þ Tregs (C) before and 4, 8, 12, 24, and 36 weeks after the study
treatments.
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treatment (1.437  1.016 copies/1000 PBMCs versus near
baseline .011  .027 copies/1000 PBMCs, P ¼ .023) and were
sustained to 36 weeks after MSC treatment. Meanwhile, the
levels of sjTREC in patients receiving MSCs was also higher at
8 weeks after the study treatment, compared with the non-
MSC group (1.437  1.016 copies/1000 PBMCs versus
.935 .641 copies/1000 PBMCs, P¼ .041) and were sustained
to 24 weeks after MSC treatment.
Toxic Side Effects
Of the 125 doses of MSC infusion, patients tolerated MSC
infusion well. None experienced any adverse events of grade
3/4 with CTCAE v3.0 [30]. At a median follow-up time of 115
days (range, 42 to 1054) after MSC treatment, secondary
tumors were not observed apart except in 1 case of EBV-
associated post-transplant lymphoproliferative disorder.
Tumor Relapse and Survival
In the MSC group, at a median follow-up time of 322.5
days (range, 49 to 1312) post-transplantation, 2 patients
relapsed, and the 3-year cumulative incidence of tumor
relapse was 17.5%  9.5%. In the control group, at a median
follow-up time of 256.5 days (range, 43 to 1024) post-
transplantation, 1 patient relapsed, and the 3-year cumula-
tive incidence of tumor relapse was 7.7%  5.4%. The
incidence of tumor relapse was not different between the 2
groups (P ¼ .725).
During the period of aGVHD treatment and follow-up, of
28 patients undergoing MSC treatment, 15 patients were
alive and 13 died. The causes of mortality included aGVHD
progression (n ¼ 3), infections (n ¼ 5), diffuse alveolar
hemorrhage (n ¼ 2), brainstem hemorrhage (n ¼ 1), post-
transplant lymphoproliferative disorder (n ¼ 1), and tumorrelapse (n ¼ 1). In the control group, 14 patients died,
including aGVHD progression (n ¼ 7), cGVHD (n ¼ 2),
infections (n ¼ 4), and relapse (n ¼ 1). The 3-year OS and
disease-free survival post-transplantation in the MSC group
were 46.4%  11.7% and 44.6%  12.6%, respectively,
compared with 26.3% 10.1% and 22.5% 8.7% in the control
group (P ¼ .115 and P ¼ .101, respectively). In addition, 3
patients in the MSC group died of hemorrhages, including 2
cases during aGVHD treatment (diffuse alveolar hemorrhage
in 1 and brainstem hemorrhage in 1) and 1 at 112 days after
last infusion of MSCs (diffuse alveolar hemorrhage). All 3
patients exhibited platelet counts no more than 10  109/L
for 2 weeks before hemorrhage and had no response to
platelet transfusion. Two patients with diffuse alveolar
hemorrhages exhibited severe mixed pulmonary infections.
Another patient with brainstem hemorrhage exhibited
hypertension and diabetes. We considered that hemorrhage
might relate to comorbidities, such as the reduction of
platelets, severe pulmonary mixed infections, and so on, but
it is worth studying further whether hemorrhages were
related to MSCs.
DISCUSSION
Since a case report in 2004 ﬁrst showed that a child with
refractory steroid-resistant aGVHD was susceptible to hap-
loidentical MSCs infusion [13], MSCs as a treatment for GVHD
have become a medical practice in many regions
[10,12,15,17,31,32]. Most studies have shown that MSCs are
effective to refractory aGVHD, which can induce a durable CR
rate of around 45% to 70% [15-17,33,34]. However, a pro-
spective study of a 2-arm trial from the United States showed
that MSCs failed to increasing the OR rate of refractory
aGVHD compared with the placebo control group [35]. The
contradictory results from these studies might be related to
K. Zhao et al. / Biol Blood Marrow Transplant 21 (2015) 97e104 103the microenvironment of MSC infusion in GVHD target or-
gans, MSC sources, andmanufacturing process [31,36]. In this
study, based on the dynamic distribution of MSCs in mice
with GVHD [37], we designed a therapeutic strategy inwhich
MSCs from BM of a third-party donor combined with pre-
existing aGVHD treatments were intravenously infused
once a week. Our results showed that 64.3% of patients had a
response after 4 weeks (doses) of MSC infusions, which had a
similar efﬁcacy to those receiving twice a week MSC
infusions over 4 weeks [15-17,33,34]. In addition, the partial
responders and nonresponders receiving subsequent weekly
MSC infusions had the potential to obtain further response.
MSCs modulate GVHD through several mechanisms,
including suppression of CD4þ and CD8þ T cell proliferation,
induction of Tregs, suppression of B cell differentiation and
proliferation, release of soluble immunomodulatory factors,
and repair of damaged target organs [31,32,38]. These studies
were mainly derived from animal models and in vitro
experiments [9,10,38], but little is known about their effects
on patients with GVHD. Recently, Jitschin et al. [39] observed
that the levels of Tregs increased and Th17 cells reduced,
type 1 T helper cells shifted toward type 2 T helper cells, and
the CD3þCD4þ/CD3þCD8þ T cell ratio increased in aGVHD
patients treated with MSCs. In this study, our results showed
the changes of peripheral immune compartment were
consistent with Jitschin et al. [39], in which the frequency of
Foxp3þ Tregs and the ratio of CD3þCD4þ/CD3þCD8þ T cells
increased. With respect to B cells in this study, we only
focused on CD19þ B cells and found no difference before and
after MSC treatment. Our previous studies showed that
CD19þ B cells decreased, but the frequencies of CD5þ regu-
latory B cells, CD27þmemory B cells, and pregerminal center
B cells increased in CR and PR cGVHD patients after MSC
treatment [40,41]. It is worth further study as to whether
MSCs also ameliorated aGVHD by modulating B cells.
Of interest, we found the incidence and severity of cGVHD
in aGVHD patients undergoing MSC treatment were
lower than those without MSC treatment. Therefore, we
proposed a hypothesis that MSCs induced long-lasting
immune tolerance by repairing damaged thymus, which
was responsible for decreasing the incidence and severity of
cGVHD. Thymus and Tregs play important roles in main-
taining central and peripheral immune tolerance, respec-
tively [42,43]. In the recipients of allo-HSCT, the toxicity of
conditioning regimen and aGVHD might disrupt thymic
structure and dysregulate the negative selection process
of potentially autoreactive T lymphocytes [42,44]. Recon-
struction of T cell compartments post-transplantation
are mainly accomplished by thymus-independent and
thymus-dependent pathways. Thymus-independent path-
ways ensure the early reconstruction of T cell compartments
post-transplantation but fail to reconstruct long-lasting
immune competence. T cell compartment reconstruction
via the thymus-independent pathway is unable to form
immune tolerance to the recipients’ antigens, but T cells are
the main effector cells in the development of aGVHD. A
complete reconstruction of T cell immune competence
depends on the thymus-dependent pathway, which is able to
form long-term immune tolerance.
The damage of thymic functionmight induce or aggravate
aGVHD [45,46]. MSCs play an important role in the initial
development and subsequent maintenance of a functional
thymic microenvironment. In mice models, MSCs could
home to thymus via intravenous infusion and MSCs were
effective to thymic GVHD treatment [44,47,48]. In this study,to prove our hypothesis, we evaluated thymic output func-
tion by sjTREC in aGVHD patients before and after the study
treatments. We found the levels of sjTREC in refractory
aGVHD patients were lower than those in healthy control
subjects, which was consistent with our previous report [23].
The levels of sjTREC increased after MSC treatment. Mean-
while, patients receiving MSC treatment exhibited higher
sjTREC levels than those without MSC treatment and sus-
tained them for a long time.
It is known that Tregs in peripheral immune compart-
ments are derived from 2 pathways: natural Tregs derived
from thymus and induced Tregs in the periphery. In this
study, we observed the frequencies of Tregs increased in
peripheral immune compartments after MSC treatment,
which might include MSCs directly inducing the generation
of Tregs in the periphery and indirectly increasing Treg
output via improving thymic function. These data all sup-
ported our hypothesis. To our knowledge, this report is the
ﬁrst description that MSCs for treating aGVHD decrease the
incidence and severity of cGVHD.
Some studies showed thatMSCsmight increase the risk of
infections and tumor relapse because of their immunosup-
pression [49,50], but contradictory reports also exist
[36,51,52]. Some studies indicated that MSCs possessed the
capacity to protect against infections, including direct effects
on the pathogen and indirect effects on the host by mobi-
lizing immune effector cells and modulating of pro-
inﬂammatory immune responses [51]. However, these data
are mainly based on in vitro experiments and the analysis of
cases. In this study, we observed the incidence of CMV and
EBV infections and tumor relapse showed no differences
between patients with and without MSC treatment, consis-
tent with our previous reports [21].
In conclusion, MSCs derived from BM of third-party
donors combined with conventional immunosuppressive
agents are effective and safe to refractory aGVHD. MSCs for
treating aGVHDmight decrease the incidence and severity of
cGVHD by improving thymic function and inducting the
generation of Tregs but do not increase the incidence of
infections and tumor relapse.
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